Market closedNon-fractional
Collegium Pharmaceutical/COLL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Collegium Pharmaceutical
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Ticker
COLL
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Stoughton, United States
Employees
197
Website
www.collegiumpharma.com
COLL Metrics
BasicAdvanced
$1.2B
Market cap
15.30
P/E ratio
$2.32
EPS
1.05
Beta
-
Dividend rate
Price and volume
Market cap
$1.2B
Beta
1.05
Financial strength
Current ratio
2.058
Quick ratio
1.88
Long term debt to equity
200.588
Total debt to equity
283.564
Interest coverage (TTM)
2.72%
Management effectiveness
Return on assets (TTM)
10.56%
Return on equity (TTM)
46.43%
Valuation
Price to earnings (TTM)
15.297
Price to revenue (TTM)
2.077
Price to book
5.17
Price to tangible book (TTM)
-3.84
Price to free cash flow (TTM)
3.821
Growth
Revenue change (TTM)
8.00%
Earnings per share change (TTM)
-367.67%
3-year revenue growth (CAGR)
20.85%
3-year earnings per share growth (CAGR)
25.28%
What the Analysts think about COLL
Analyst Ratings
Majority rating from 6 analysts.
COLL Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$145M
-3.21%
Net income
$28M
-13.17%
Profit margin
19.11%
-10.28%
COLL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.34
$0.53
$0.82
$1.45
-
Expected
$0.29
$0.52
$0.66
$0.94
$1.49
Surprise
18.26%
2.58%
24.24%
54.50%
-
COLL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Collegium Pharmaceutical stock?
Collegium Pharmaceutical (COLL) has a market cap of $1.2B as of July 27, 2024.
What is the P/E ratio for Collegium Pharmaceutical stock?
The price to earnings (P/E) ratio for Collegium Pharmaceutical (COLL) stock is 15.3 as of July 27, 2024.
Does Collegium Pharmaceutical stock pay dividends?
No, Collegium Pharmaceutical (COLL) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Collegium Pharmaceutical dividend payment date?
Collegium Pharmaceutical (COLL) stock does not pay dividends to its shareholders.
What is the beta indicator for Collegium Pharmaceutical?
Collegium Pharmaceutical (COLL) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Collegium Pharmaceutical stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.